Efficacy of Recombinant Human Vascular Endostatin Combined with Compound Kushen Injection by Intraperitoneal Infusion in the Treatment of Malignant Peritoneal Effusion of Gastrointestinal Tumors
OBJECTIVE:To probe into the clinical efficacy and safety of recombinant human vascular endostatin combined with compound Kushen injection by intraperitoneal infusion in the treatment of malignant peritoneal effusion of gastrointestinal tumors.METHODS:This study was a prospective study,92 patients with malignant peritoneal effusion of gastrointestinal tumors admitted into the hospital from Aug.2020 to Feb.2023 were extracted to be divided into the control group(46 cases,5-fluorouracil)and observation group(46 cases,recombinant human vascular endostatin+compound Kushen injection)according to the random number table method.After treatment of 3 weeks,the clinical efficacy,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),and carbohydrate antigen 125(CA125)]levels and incidence of adverse drug reactions were compared between two groups.RESULTS:After 3 weeks of continuous peritoneal perfusion,the objective response rate in the observation group was higher than that in the control group[71.74%(33/46)vs.39.13%(18/46)],with statically significant difference(P<0.05).After treatment of 3 weeks,the serum tumor markers(CEA,CA199,and CA125)in two groups decreased,and the observation group was lower than the control group,with statically significant difference(P<0.05).During the treatment period,the incidence of blood cytotoxicity in the observation group was 8.70%(4/46),significantly lower than 32.61%(15/46)in the control group,and the overall incidence of adverse drug reactions in the observation group were lower than that in control group[36.96%(17/46)vs.71.74%(33/46)],with statically significant difference(P<0.05).CONCLUSIONS:Recombinant human vascular endostatin combined with compound Kushen injection in the treatment of malignant peritoneal effusion of gastrointestinal tumors can effectively control disease progression,improve the clinical symptoms and disease prognosis of patients,with higher safety.
Gastrointestinal tumorsMalignant peritoneal effusionRecombinant human vascular endostatinCompound Kushen injection
国家科技期刊平台
NSTL
万方数据
